Literature DB >> 16423994

Gene conversion is a frequent mechanism of inactivation of the wild-type allele in cancers from MLH1/MSH2 deletion carriers.

Jian Zhang1, Annette Lindroos, Saara Ollila, Anna Russell, Giancarlo Marra, Hansjakob Mueller, Paivi Peltomaki, Martina Plasilova, Karl Heinimann.   

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominantly inherited cancer predisposition syndrome caused by germ line mutations in DNA mismatch repair genes, predominantly MLH1 and MSH2, with large genomic rearrangements accounting for 5% to 20% of all mutations. Although crucial to the understanding of cancer initiation, little is known about the second, somatic hit in HNPCC tumorigenesis, commonly referred to as loss of heterozygosity. Here, we applied a recently developed method, multiplex ligation-dependent probe amplification, to study MLH1/MSH2 copy number changes in 16 unrelated Swiss HNPCC patients, whose cancers displayed microsatellite instability and loss of MLH1 or MSH2 expression, but in whom no germ line mutation could be detected by conventional screening. The aims of the study were (a) to determine the proportion of large genomic rearrangements among Swiss MLH1/MSH2 mutation carriers and (b) to investigate the frequency and nature of loss of heterozygosity as a second, somatic event, in tumors from MLH1/MSH2 germ line deletion carriers. Large genomic deletions were found to account for 4.3% and 10.7% of MLH1 and MSH2 mutations, respectively. Multiplex ligation-dependent probe amplification analysis of 18 cancer specimens from two independent sets of Swiss and Finnish MLH1/MSH2 deletion carriers revealed that somatic mutations identical to the ones in the germ line occur frequently in colorectal cancers (6 of 11; 55%) and are also present in extracolonic HNPCC-associated tumors. Chromosome-specific marker analysis implies that loss of the wild-type allele predominantly occurs through locus-restricted recombinational events, i.e., gene conversion, rather than mitotic recombination or deletion of the respective gene locus. (Cancer Res 2006; (66)2: 659-64).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16423994     DOI: 10.1158/0008-5472.CAN-05-4043

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.

Authors:  Ian F Pollack; Ronald L Hamilton; Robert W Sobol; Marina N Nikiforova; Yuri E Nikiforov; Maureen A Lyons-Weiler; William A LaFramboise; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Floyd H Gilles; Allan J Yates; Tianni Zhou; Kenneth J Cohen; Jonathan L Finlay; Regina I Jakacki
Journal:  Pediatr Blood Cancer       Date:  2010-12-01       Impact factor: 3.167

2.  Assessment of anti-recombination and double-strand break-induced gene conversion in human cells by a chromosomal reporter.

Authors:  Keqian Xu; Xiling Wu; Joshua D Tompkins; Chengtao Her
Journal:  J Biol Chem       Date:  2012-07-07       Impact factor: 5.157

3.  MYH biallelic mutation can inactivate the two genetic pathways of colorectal cancer by APC or MLH1 transversions.

Authors:  Jérémie H Lefevre; Chrystelle Colas; Florence Coulet; Carolina Bonilla; Najat Mourra; Jean-Francois Flejou; Emmanuel Tiret; Walter Bodmer; Florent Soubrier; Yann Parc
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

4.  Two novel mutations in hMLH1 gene in Iranian hereditary non-polyposis colorectal cancer patients.

Authors:  Somayeh Shahmoradi; Ali Bidmeshkipour; Ahmad Salamian; Mohammad Hasan Emami; Zahra Kazemi; Mansoor Salehi
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

5.  Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study.

Authors:  A Gylling; W M Abdel-Rahman; M Juhola; K Nuorva; E Hautala; H J Järvinen; J-P Mecklin; M Aarnio; P Peltomäki
Journal:  Gut       Date:  2007-01-31       Impact factor: 23.059

6.  UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.

Authors:  Youfeng Yang; Vladimir A Valera; Hesed M Padilla-Nash; Carole Sourbier; Cathy D Vocke; Manish A Vira; Mones S Abu-Asab; Gennady Bratslavsky; Maria Tsokos; Maria J Merino; Peter A Pinto; Ramaprasad Srinivasan; Thomas Ried; Len Neckers; W Marston Linehan
Journal:  Cancer Genet Cytogenet       Date:  2010-01-01

7.  Identification and characterization of a novel MLH1 genomic rearrangement as the cause of HNPCC in a Tunisian family: evidence for a homologous Alu-mediated recombination.

Authors:  Sana Aissi-Ben Moussa; Amel Moussa; Tonio Lovecchio; Nadia Kourda; Taoufik Najjar; Sarra Ben Jilani; Amel El Gaaied; Nicole Porchet; Mohamed Manai; Marie-Pierre Buisine
Journal:  Fam Cancer       Date:  2008-09-16       Impact factor: 2.375

Review 8.  The impact of recombination on human mutation load and disease.

Authors:  Isabel Alves; Armande Ang Houle; Julie G Hussin; Philip Awadalla
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-12-19       Impact factor: 6.237

9.  Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.

Authors:  Sigurdis Haraldsdottir; Heather Hampel; Jerneja Tomsic; Wendy L Frankel; Rachel Pearlman; Albert de la Chapelle; Colin C Pritchard
Journal:  Gastroenterology       Date:  2014-09-03       Impact factor: 22.682

10.  Partial loss of heterozygosity events at the mutated gene in tumors from MLH1/MSH2 large genomic rearrangement carriers.

Authors:  Katarina Zavodna; Tomas Krivulcik; Maria Gerykova Bujalkova; Tomas Slamka; David Martinicky; Denisa Ilencikova; Zdena Bartosova
Journal:  BMC Cancer       Date:  2009-11-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.